During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Nearly four million patients with asthma or chronic obstructive pulmonary disease (COPD ... dosing regimens given with placebo. The group taking prednisolone alone had a 74% treatment failure ...

Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Breathing is essential for life, yet for many individuals suffering from chronic respiratory issues such as asthma and COPD, ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...

Far from simply dispensing medications, pharmacists are vital members of medical teams, particularly in primary care settings ...

The following is a summary of “Feasibility, Usability, and Pilot Efficacy Study of a Software-Enabled, Virtual Pulmonary ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...